Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

181. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 28768311 2018 11 13 2380-6591 2 9 2017 Sep 01 JAMA cardiology JAMA Cardiol Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. 995-1006 10.1001/jamacardio.2017.2511 Among myriad changes occurring during the evolution (...) of heart failure with preserved ejection fraction (HFpEF), cardiomyocyte-extracellular matrix interactions from excess collagen may affect microvascular, mechanical, and electrical function. To investigate whether myocardial fibrosis (MF) is similarly prevalent both in those with HFpEF and those at risk for HFpEF, similarly associating with disease severity and outcomes. Observational cohort study from June 1, 2010, to September 17, 2015, with follow-up until December 14, 2015, at a cardiovascular

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

182. Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey

Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey 28921886 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. 172-183 10.1002/ehf2.12205 CORE is a continuing medical education initiative designed to support the evidence-based management of heart failure (...) (HF) in the primary and secondary care settings. The goal of the CORE Needs Assessment Survey is to describe current clinical practice patterns and attitudes among global stakeholders in HF care. The CORE Steering Committee guided the development of survey questions to assess clinical practice, confidence, and attitudes/perceptions among cardiologists, primary care physicians, and nurses involved in HF management. In total, 346 healthcare professionals from Australia (n = 59), Austria (n = 59

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

183. Impaired renal function affects clinical outcomes and management of patients with heart failure

Impaired renal function affects clinical outcomes and management of patients with heart failure 28872780 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail Impaired renal function affects clinical outcomes and management of patients with heart failure. 576-584 10.1002/ehf2.12185 Inpatients with heart failure and renal impairment have poor outcomes and variable quality of care. We investigate treatment practice and outcomes in an unselected real-world cohort using (...) historical creatinine measurements. Admissions between 1/4/2013 and 30/4/2015 diagnosed at discharge with heart failure were retrospectively analysed. Stages of chronic kidney disease (CKD) and acute kidney injury (AKI) were calculated from creatinine at discharge and 3-12 months before admission. We identified 1056 admissions of 851 patients (mean age 76 years, 56% Caucasian, 36% with diabetes mellitus, 54% with ischaemic heart disease, and 57% with valvular heart disease). CKD was common; 36%-Stage 3a

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

184. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure

Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure 28859790 2017 09 01 2017 09 13 2017 09 13 1558-3597 70 10 2017 Sep 05 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. 1262-1272 S0735-1097(17)38815-0 10.1016/j.jacc.2017.07.725 Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown (...) promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms. This was a randomized, double-blind, placebo-controlled, phase II/III study with 12

EvidenceUpdates2017

185. Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices

Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices 28784235 2017 08 08 2017 09 14 2017 09 14 1879-1913 120 7 2017 Oct 01 The American journal of cardiology Am. J. Cardiol. Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices. 1158-1165 S0002-9149(17)31118-9 10.1016/j.amjcard.2017.06.056 Age is an adverse (...) prognostic factor in patients with heart failure. We aimed to assess the impact of age and noncardiac co-morbidities in the outcome of patients undergoing cardiac resynchronization therapy (CRT), and determine which of these two factors is the most important predictor of survival. The study involved a single-center retrospective assessment of 697 consecutive CRT implants during a 12-year period. Patient co-morbidity profile was assessed using the Charlson Co-morbidity Index (CCI) and the Charlson Age-Co

EvidenceUpdates2017

186. An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study)

An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study) 28772186 2017 08 03 2017 09 22 1873-491X 75 2017 Jul 25 International journal of nursing studies Int J Nurs Stud An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study). 101-111 S0020-7489(17)30167-0 10.1016/j.ijnurstu.2017.07.015 (...) The prevalence of heart failure is increasing in Lebanon but to date there is no systematic evaluation of a disease management intervention. The aim of this study was to evaluate the effect of involving family caregivers in the self-care of patients with heart failure on the risk of hospital readmission. A multi-site, block randomised controlled trial. The study was conducted over a 13-month period in three tertiary medical centres in Beirut and Mount Lebanon, Lebanon. Adult patients presenting

EvidenceUpdates2017

187. Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction?

Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? | Clinical Correlations Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? August 23, 2017 By Lauren Christene Strazzulla Peer Reviewed The lifetime risk for developing heart failure from age 55 on is 33% for men and 28.5% for women, and as the population ages, there is an increasing [1, 2]. Heart failure is (...) divisible into 2 distinct entities: those with left ventricular systolic dysfunction and those with cardiovascular compromise that does not decrease LV ejection fraction, which is [3]. While these 2 subgroups may present similarly, they develop through different pathophysiological mechanisms. In heart failure with reduced ejection fraction (HFrEF), systolic function is impaired [4]. On the other hand, HFpEF is a heterogeneous and poorly understood condition, and its exact causes remain unclear

Clinical Correlations2017

188. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark

Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark 28774428 2017 08 04 2017 09 01 2017 09 01 1879-1913 120 6 2017 Sep 15 The American journal of cardiology Am. J. Cardiol. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark. 980-985 S0002-9149(17)31035-4 10.1016/j.amjcard.2017.06.027 Research on the association between schizophrenia and the quality of care and clinical outcomes of heart failure (HF) remains sparse (...) . This nationwide study compared the quality of care and clinical outcomes of HF among Danish patients with and without schizophrenia. In a population-based cohort study, we identified 36,718 patients with incident HF with hospital contacts, including 108 with schizophrenia, using Danish registries between 2004 and 2013. High quality of HF care was defined as receiving ≥ 80% guideline-recommended process-performance measures of care. Potential predictors of HF care among patients with schizophrenia included

EvidenceUpdates2017

189. Entresto (sacubitril, valsartan) - treatment of heart failure

Entresto (sacubitril, valsartan) - treatment of heart failure Entresto (sacubitril, valsartan) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Entresto (sacubitril, valsartan) Conclusion Entresto is the first medicine in the class of combined angiotensin receptor neprilysin inhibitors (ARNI) containing valsartan and sacubitril. It is indicated for the treatment of heart failure as an alternative to angiotensin converting enzyme (ACE (...) ) inhibitors/angiotensin II receptor blockers (ARB). The active ingredient has proven to have a convincing effect on both survival and readmission rates in patients with heart failure who remain symptomatic despite treatment with ACE inhibitors/ARBs at the maximum dose. Treatment should primarily be started by cardiologists experienced in the treatment of patients with heart failure. It is expected that the monitoring of patients up-titrated to the maintenance dose of Entresto are transferred to their GPs. The profile

Danish Pharmacotherapy Reviews2017

191. Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)?

Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? View/ Open Date (...) 2017-07 Format Metadata Abstract Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Evidence-based answer: There is concern. Beta-agonist use is associated with a dose-dependent increase in all-cause mortality and heart failure (HF) hospitalization in patients with known HF. Beta-agonist use is also associated with increased vasodilator use and mechanical ventilation in patients admitted for acute decompensated HF (SOR: B, 2 cohort study and 1 case-control study

Evidence Based Practice 2017

192. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with inconsistent results. Objective: To determine whether an amino (...) -terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical outcomes vs usual care in high-risk patients with HF and reduced ejection fraction (HFrEF). Design, Settings, and Participants: The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study was a randomized multicenter clinical trial conducted between January 16, 2013, and September 20, 2016, at 45 clinical sites in the United States and Canada. This study planned

JAMA2017 Full Text: Link to full Text with Trip Pro

193. Association between vitamin D deficiency and heart failure risk in the elderly

Association between vitamin D deficiency and heart failure risk in the elderly 28817241 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Association between vitamin D deficiency and heart failure risk in the elderly. 63-74 10.1002/ehf2.12198 The aim of this study was to evaluate the association between vitamin D deficiency and risk of heart failure in elderly patients of cardiology outpatient clinics. A cross-sectional study with an analytical approach was employed (...) . Clinical data were collected from the elderly from August 2015 to February 2016. The dependent variable was the risk of heart failure; the independent variable was vitamin D deficiency; and intervening factors were age, gender, education, ethnicity, hypertension, diabetes mellitus, hypothyroidism, renal failure, dementia, stroke, dyslipidaemia, depression, smoking, alcoholism, obesity, andropause, and cardiac arrhythmia. To analyse the association between vitamin D deficiency and risk of heart failure

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

194. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model Journals Library An error occurred retrieving content (...) to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The efficacy of BNP-guided-therapy in specialist heart failure clinics is uncertain, but if efficacious, it would be cost-effective for patients under 75 with reduced ejection

NIHR HTA programme2017

195. High body mass index is a predictor of left ventricular reverse remodelling in heart failure with reduced ejection fraction

High body mass index is a predictor of left ventricular reverse remodelling in heart failure with reduced ejection fraction 28752617 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail High body mass index is a predictor of left ventricular reverse remodelling in heart failure with reduced ejection fraction. 686-689 10.1002/ehf2.12172 Structural and functional left ventricular alterations can occur in heart failure (HF), referred to as left ventricular reverse (...) in indexed left ventricular end-diastolic diameter ≥10%. Clinical follow-up was also obtained. LVRR occurred in 53 (18%) patients. Patients in the LVRR group were more likely to present with de novo HF (75% vs. 42%), had lower LVEF and left ventricular end-diastolic volumes at index examination, yet a higher body mass index (BMI) than non-LVRR patients. Obesity was observed in 25% of LVRR patients vs. 14% in others. In multivariate analyses, BMI (per each 1 kg/m 2 increase) emerged as a predictor of LVRR

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

196. Cost‐effectiveness of left ventricular assist devices for patients with end‐stage heart failure: analysis of the French hospital discharge database

Cost‐effectiveness of left ventricular assist devices for patients with end‐stage heart failure: analysis of the French hospital discharge database 28741873 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database. 75-86 10.1002/ehf2.12194 Although left ventricular assist devices (LVADs) are currently approved for coverage (...) , delivering a probabilistic ICER of €125 580/QALY [95% confidence interval: 105 587 to 150 314]. The sensitivity analysis showed that the ICER was mainly sensitive to two factors: (i) the high acquisition cost of the device and (ii) the device performance in terms of patient survival. Our economic evaluation showed that the use of LVAD in patients with end-stage heart failure yields greater benefit in terms of survival than medical management at an extra lifetime cost exceeding the €100 000/QALY

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

197. A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort 28741909 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. 19-26 10.1002/ehf2.12200 Heart failure with a preserved ejection fraction (HF-PEF) remains a difficult clinical diagnosis. The aim (...) of this study was to test the utility of established criteria to classify patients with HF-PEF. We prospectively enrolled patients into one of five groups across a spectrum of cardiac disease and applied three different criteria for HF-PEF and calculated diagnostic metrics. A total of 565 patients were included in the analysis, including 170 patients with an adjudicated diagnosis of HF-PEF, 152 patients with heart failure with reduced ejection fraction, 152 patients at risk for heart failure, and 91 age

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

198. Recovery free of heart failure after acute coronary syndrome and coronary revascularization

Recovery free of heart failure after acute coronary syndrome and coronary revascularization 28737273 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Recovery free of heart failure after acute coronary syndrome and coronary revascularization. 107-114 10.1002/ehf2.12197 Previous studies have examined risk factors for the development of heart failure (HF) subsequent to acute coronary syndrome (ACS). Our study seeks to clarify the clinical variables that best (...) characterize patients who remain free from HF after coronary artery bypass grafting (CABG) surgery for ACS to determine novel biological factors favouring freedom from HF in prospective translational studies. Nova Scotia residents (1995-2012) undergoing CABG within 3 weeks of ACS were included. The primary outcome was freedom from readmission to hospital due to HF. Descriptive statistics were generated, and a Cox proportional hazards model assessed outcome with adjustment for clinical characteristics

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

199. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial

Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial 28724134 2018 11 13 2380-6591 2 7 2017 Jul 01 JAMA cardiology JAMA Cardiol Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. 767-774 10.1001/jamacardio (...) collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which randomly assigned 2521 patients to placebo, amiodarone, or ICD between 1997 and 2001. A subset of 1902 participants (75.4%) of the SCD-HeFT had a repeated assessment of EF a mean (SD) of 13.5 (6) months after randomization. We stratified these patients by EF ≤35% and >35% based on the first repeated EF measurement after randomization and compared all-cause mortality in 649 patients randomized to placebo vs 624 patients

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

200. High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study

High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study 29045610 2018 11 13 2058-1742 4 1 2018 01 01 European heart journal. Quality of care & clinical outcomes Eur Heart J Qual Care Clin Outcomes High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. 36-42 10.1093/ehjqcco/qcx022 Heart failure may occur following acute myocardial (...) infarction, but with the use of high-sensitivity cardiac troponin assays we increasingly diagnose patients with minor myocardial injury. Whether troponin concentrations remain a useful predictor of heart failure in patients with acute coronary syndrome is uncertain. We identified all consecutive patients (n = 4748) with suspected acute coronary syndrome (61 ± 16 years, 57% male) presenting to three secondary and tertiary care hospitals. Cox-regression models were used to evaluate the association between high-sensitivity

European heart journal. Quality of care & clinical outcomes2017 Full Text: Link to full Text with Trip Pro